Achieving the Vision
Roche remains committed to the advancement of transplantation through ongoing research. We are focused on addressing critical issues in transplantation that directly improve patient care.
The art of transplantation has come a long way since the first solid organ (kidney) was transplanted in 1954. The driving force behind this progress has been quality clinical research and dedicated researchers.
Roche is proud of the role that we have played in the advancement of transplant medicine and look forward to the future.
Currently, Roche is focusing its resources on further exploring several key areas, including:
- The improvement of graft function and minimizing nephrotoxicity (Spare the Nephron – STN)
- Improvement of patient outcomes through therapeutic drug monitoring (OptiCeptTM)
- Protecting patients against the late onset of CMV disease (IMPACTTM)
|
Spare the Nephron (STN) Studies |
 |
|
|
|
OptiCeptTM – Studying therapeutic drug monitoring (TDM) |
|
|
|
|
IMPACTTM – Studying duration of CMV prophylaxis |
|
|
|
|
Other Clinical Trials Links |
|
|